Human Reproduction, Vol. 17, No. 8, 2107-2111,
August 2002
© 2002 European Society of Human Reproduction and Embryology
Ovarian stimulation in intrauterine insemination with donor sperm: a randomized study comparing clomiphene citrate in fixed protocol versus highly purified urinary FSH
1 Human Reproductive Unit, Department of Obstetrics and Gynecology and 2 Clinical Epidemiology Unit, País Vasco University, Hospital from Cruces, Baracaldo, Vizcaya, Spain
BACKGROUND: The study was conducted to compare the results of intrauterine donor insemination (DI) under ovarian stimulation with either clomiphene citrate (CC), in a fixed protocol, or FSH, with ovarian monitoring. METHODS: Forty-nine patients were randomized using a computer-generated list to receive highly purified urinary FSH (starting dose of 150 IU) and were subjected to periodic vaginal ultrasound and estradiol determinations. HCG was given when 
2 follicles (17 mm) were identified and estradiol reached >400 pg/ml. Intrauterine insemination (IUI) was performed 36 h later. The other 51 received CC on a fixed protocol (100 mg/day from the day 5–10 of the ovarian cycle) with HCG being administered on the day 12, and IUI performed 36 h later. Up to six IUI cycles were performed on all patients if pregnancy was not reached before. Women failing to conceive in the CC group underwent IUI with FSH. The main outcome measures were intrauterine gestational sac observed by transvaginal ultrasound, per cycle and per woman pregnancy rate (PR) and multiple PR. RESULTS: The per cycle PR was significantly higher in the FSH group, 14.4% (30/209) versus 6.1% (16/261), as well as the per woman PR, 61.2% (30/49) versus 31.4% (16/51). 12.5% (2/16) of pregnancies obtained in the CC group were multiple, compared with 20% (6/30) in the FSH group. There were no triplets or higher order pregnancies in CC versus two in FSH (6.7% of pregnancies). Patients failing to conceive with CC, who later underwent intrauterine DI with FSH, had similar results to the primary FSH group: 54.3% PR per patient (19/35) and 16.0% per cycle (19/118), with a multiple PR of 31.6% (6/19). The PR for women starting with CC cycles and, if pregnancy was not obtained, continuing with six FSH cycles, was 69.2%. CONCLUSIONS: The PR obtained with CC stimulation was approximately half that obtained with FSH. There was a trend to lower multiple PR with CC. It is recommended that each case should be considered on an individual basis and the treatment options discussed with patients. In our opinion, CC could be a reasonable approach for young women with good prognosis, whereas in the remaining cases FSH would be the preferable method.
Key words: clomiphene citrate stimulation/FSH stimulation/intrauterine donor insemination/pregnancy rate/prospective randomized trial
3 To whom correspondence should be addressed at: María Diaz de Haro 7, 6iz. 48013 Bilbao, Spain. E-mail: rmatorras{at}hcru.osakidetza.net
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  The ESHRE Capri Workshop Group Intrauterine insemination Hum. Reprod. Update, May 1, 2009; 15(3): 265 - 277. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Dankert, J.A.M. Kremer, B.J. Cohlen, C.J.C.M. Hamilton, P.C.M. Pasker-de Jong, H. Straatman, and P.A. van Dop A randomized clinical trial of clomiphene citrate versus low dose recombinant FSH for ovarian hyperstimulation in intrauterine insemination cycles for unexplained and male subfertility Hum. Reprod., March 1, 2007; 22(3): 792 - 797. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Allegra, A. Marino, F. Coffaro, P. Scaglione, F. Sammartano, G. Rizza, and A. Volpes GnRH antagonist-induced inhibition of the premature LH surge increases pregnancy rates in IUI-stimulated cycles. A prospective randomized trial Hum. Reprod., January 1, 2007; 22(1): 101 - 108. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Dias, R. McNamee, and A. Vail Evidence of improving quality of reporting of randomized controlled trials in subfertility Hum. Reprod., October 1, 2006; 21(10): 2617 - 2627. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C.B. Lambalk, A. Leader, F. Olivennes, M.R. Fluker, A. N. Andersen, J. Ingerslev, Y. Khalaf, C. Avril, J. Belaisch-Allart, R. Roulier, et al. Treatment with the GnRH antagonist ganirelix prevents premature LH rises and luteinization in stimulated intrauterine insemination: results of a double-blind, placebo-controlled, multicentre trial Hum. Reprod., March 1, 2006; 21(3): 632 - 639. [Abstract] [Full Text] [PDF]
|
|